Burkitt Leukemia

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

ABL1
BCR
BCR-ABL1
BCR-ABL1 Fusion
CD22 Expression
MS4A1 Expression
Trisomy 21
t(9;22)(q34;q11)

Overview

NCI Definition: The leukemic counterpart of Burkitt's lymphoma. The characteristic Burkitt cells are seen in the bone marrow and the peripheral blood. This is an aggressive leukemia. [1]

Clinical Trials

View Clinical Trials for Burkitt Leukemia

There are 10 clinical trials for Burkitt leukemia, of which 9 are open and 1 is completed or closed. Of the trials that contain Burkitt leukemia as an inclusion criterion, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (4 open).

CD22 and MS4A1 are the most frequent gene inclusion criteria for Burkitt leukemia clinical trials [3].

Trials Investigating Burkitt Leukemia by Gene and Recruiting Status

Cyclophosphamide, melphalan, and rituximab are the most common interventions in Burkitt leukemia clinical trials.

Drugs Being Investigated in Burkitt Leukemia Trials by Recruiting Status

Significant Genes in Burkitt Leukemia

ABL1 +

ABL1 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain ABL1 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

AFF1 +

AFF1 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain AFF1 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

BCL2 +

BCL2 is an inclusion eligibility criterion in 3 clinical trials for Burkitt leukemia, of which 3 are open and 0 are closed. Of the trials that contain BCL2 status and Burkitt leukemia as inclusion criteria, 3 are phase 2 (3 open) [3].

BCL6 +

BCL6 is an inclusion eligibility criterion in 3 clinical trials for Burkitt leukemia, of which 3 are open and 0 are closed. Of the trials that contain BCL6 status and Burkitt leukemia as inclusion criteria, 3 are phase 2 (3 open) [3].

BCR +

BCR is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain BCR status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

DEK +

DEK is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain DEK status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

ELL +

ELL is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain ELL status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

FLT3 +

FLT3 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain FLT3 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

KMT2A +

KMT2A is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain KMT2A status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

MECOM +

MECOM is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

MLLT1 +

MLLT1 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT1 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

MLLT10 +

MLLT10 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT10 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

MLLT3 +

MLLT3 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT3 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

MLLT4 +

MLLT4 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain MLLT4 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

MYC +

MYC is an inclusion eligibility criterion in 3 clinical trials for Burkitt leukemia, of which 3 are open and 0 are closed. Of the trials that contain MYC status and Burkitt leukemia as inclusion criteria, 3 are phase 2 (3 open) [3].

NRIP3 +

NRIP3 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain NRIP3 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

NUP214 +

NUP214 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain NUP214 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

PBX1 +

PBX1 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain PBX1 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

RPN1 +

RPN1 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain RPN1 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

TCF3 +

TCF3 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain TCF3 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

TP53 +

TP53 is an inclusion eligibility criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain TP53 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [3].

Disease Details

Synonyms

L3 Acute Lymphoid Leukemia, Burkitt lymphoma/leukemia, L3 Acute Lymphogenous Leukemia, FAB L3, L3 Acute Lymphoblastic Leukemia, Burkitt's Leukemia, L3 Acute Lymphocytic Leukemia, Burkitt's Cell Leukemia

Parent(s)

Lymphoid Leukemia

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.